Drug-coated balloon in peripheral artery disease
- PMID: 29730237
- DOI: 10.1016/j.carrev.2018.04.017
Drug-coated balloon in peripheral artery disease
Abstract
Peripheral artery disease (PAD) is highly prevalent but is often underdiagnosed and undertreated. Lower extremity PAD can often be life style limiting. Revascularization in carefully selected lower extremity PAD patients improves symptoms and functional status. Surgical revascularization used to be the only available strategy, but in the recent years, endovascular strategies have gained popularity due to faster recovery times with low morbidity and mortality rates. Endovascular procedures have increased significantly in the United States in the past few years. That being said, higher restenosis rates and low long-term patency rates have been the limiting factors for this strategy. Drug eluting stents have been introduced to help with lowering restenosis, however lower extremity PAD involves long segment where the outcomes of stents are suboptimal. Also, the disease often crosses joint line that makes it less ideal for the stents. Drug-coated balloons (DCB) have been introduced to improve patency rates following endovascular intervention for lower extremity PAD. They have gained popularity among endovascular specialists due to its ease of use and the concept of "leave nothing behind". This is a review of scientific evidence supporting DCB use in PAD.
Keywords: Drug-coated balloon; Endovascular interventions; Peripheral artery disease.
Published by Elsevier Inc.
Comment in
-
Paclitaxel Drug-Coated Balloons in Peripheral Artery Disease: Who's Trying to Shoot the Football Star?Cardiovasc Revasc Med. 2019 Apr;20(4):285-286. doi: 10.1016/j.carrev.2019.02.006. Cardiovasc Revasc Med. 2019. PMID: 31023546 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources